Methods: A total of 392 patients with seasonal allergic rhinitis were selected from the population of the epidemiological investigation project of allergic diseases in Hohhot, Inner Mongolia. The project was led by Department of Allergy, Beijing Shijitan Hospital, Capital Medical University, and assisted by Hohhot First Hospital from April to May 2023. The patients were randomly divided into a spleen aminopeptide group (296 cases) and control group (96 cases) at a ratio of 3∶1, and the enrollment period was from June 1 to 14, 2023. The treatment group was treated with spleen aminopeptide oral solution for 12 weeks starting from 4-6 weeks (±7 days) before the pollen dispersal period, while the control group was treated with a simulated agent of spleen aminopeptide oral solution. Both the treatment group and the control group were treated with oral antihistamines and/or nasal glucocorticoids as needed during the pollen dispersal period. Evaluate the therapeutic effect by comparing the symptom scores, drug scores and quality of life scores of the two groups, and detect the expression levels of cytokines in serum. Symptom scores, quality of life scores, drug scores and laboratory results were compared by independent sample t test/Kruskal-Wallis test and χ2 test/Fisher\'s exact test. Results: Compared with the control group, spleen aminopeptide treatment for 12 weeks significantly improved symptoms of nasal congestion [M(Q1,Q3):2(1, 2) vs. 2(1, 3), H=6.308, P<0.05], nasal itching [M(Q1,Q3):2(1, 2) vs. 2(1, 3), H=4.966, P<0.05], sneezing [M(Q1,Q3):2(1, 2) vs. 2(1, 3), H=5.245, P<0.05], runny nose [M(Q1,Q3):2(1, 2) vs. 2(1, 3), H=5.41, P<0.05] and tearing [M(Q1,Q3):1(0, 2) vs. 1(0, 3), H=4.664, P<0.05]. At 12 weeks of treatment, the scores of nasal symptoms and ocular symptoms in control group and experimental group were significantly increased compared with baseline (P<0.05). In experimental group, nasal congestion [M(Q1,Q3):1(0, 1) vs. 1(0, 2), H=4.042, P<0.05], eye itching/foreign body sensation/redness symptom scores [M(Q1,Q3):1(0, 2) vs. 1(0, 2), H=5.302, P<0.05] and total scores [M(Q1,Q3):4(-1, 9) vs. 5(0, 12.5), H=3.958, P<0.05] were significantly increased. The antihistamine drug score of the splenic peptide treatment group at 6 weeks were lower than that of the control group (H=4.232, P<0.05). After 12 weeks of treatment, the antihistamine drug score [M(Q1,Q3):10(0, 24) vs. 19(2, 36.5), H=6.67, P<0.05] and the total drug score [M(Q1,Q3):28.5(5, 77.5) vs. 46(6, 155.5), H=3.995, P<0.05] were significantly lower than those of the control group. The serum IL-17A levels of the treatment group were significantly lower than those of the control group after 6 weeks (0.7±1.77 vs. 0.85±1.67,H=10.08, P<0.05) and 12 weeks (0.81±1.63 vs. 0.94±1.73,H=5.196, P<0.05) of splenic aminopeptide treatment. Conclusions: Early treatment with spleen aminopeptide oral solution can significantly improve nasal and ocular symptoms of patients with seasonal allergic rhinitis, reduce the use of drugs during the onset period, and improve the quality of life. It may exert an immunomodulatory effect by reducing the expression level of IL-17A in the serum of patients. Objects: To conduct a study on the prevention and treatment of seasonal allergic rhinitis in Hohhot, Inner Mongolia, evaluate the preventive and therapeutic effects of spleen aminopeptide oral solution on seasonal allergic rhinitis, and explore its related mechanisms.
目的： 开展内蒙古呼和浩特地区季节性过敏性鼻炎防治的研究，探讨脾氨肽口服溶液对季节性过敏性鼻炎的预防与治疗作用，以及其相关机制。 方法： 于2023年4—5月首都医科大学附属北京世纪坛医院变态反应科牵头，呼和浩特市第一医院协助开展的内蒙古呼和浩特地区过敏性疾病流行病学调查项目的流调人群中，选取392例季节性过敏性鼻炎患者，按3∶1随机分为脾氨肽治疗组（296例）和对照组（96例），并在2023年6月1—14日完成入组。治疗组在花粉播散期前4~6周（±7 d）开始应用脾氨肽口服溶液治疗12周，对照组应用脾氨肽口服溶液模拟剂，治疗组和对照组在花粉播散期间均按需使用口服抗组胺药物和/或鼻用糖皮质激素治疗。通过对比两组人群的症状评分、药物评分和生活质量评分评估疗效，并检测血清中多种细胞因子的表达水平。采用独立样本t检验/Kruskal-Wallis检验、χ2 检验/Fisher 精确检验比较症状评分、生活质量评分、药物评分和实验室检查。 结果： 与对照组相比，脾氨肽治疗12周可显著改善鼻塞［M（Q1，Q3）：2（1，2）vs. 2（1，3），H值=6.308，P<0.05］、鼻痒［M（Q1，Q3）：2（1，2）vs. 2（1，3），H值=4.966，P<0.05］、喷嚏［M（Q1，Q3）：2（1，2）vs. 2（1，3），H值=5.245，P<0.05］、流涕［M（Q1，Q3）：2（1，2）vs. 2（1，3），H值=5.41，P<0.05］、流泪［M（Q1，Q3）：1（0，2）vs. 1（0，3），H值=4.664，P<0.05］症状。治疗12周时对照组和试验组鼻部症状及眼部症状评分与基线相比均升高（P<0.05），试验组鼻塞［M（Q1，Q3）：1（0，1）vs. 1（0，2），H值=4.042，P<0.05］、眼痒/异物感/眼红［M（Q1，Q3）：1（0，2）vs. 1（0，2），H值=5.302，P<0.05］症状评分及总评分［M（Q1，Q3）：4（-1，9）vs. 5（0，12.5），H值=3.958，P<0.05］升高的幅度低于对照组。脾氨肽治疗组治疗6周抗组胺药物评分低于对照组（H值=4.232，P<0.05）；治疗12周时，抗组胺药物评分［M（Q1，Q3）：10（0，24）vs. 19（2，36.5），H值=6.67，P<0.05］及药物总评分［M（Q1，Q3）：28.5（5，77.5）vs. 46（6，155.5），H值=3.995，P<0.05］均低于对照组。在脾氨肽治疗6周（0.7±1.77 vs. 0.85±1.67，H值=10.08，P<0.05）和12周（0.81±1.63 vs. 0.94±1.73，H值=5.196，P<0.05）时，治疗组血清IL-17A水平均低于对照组。 结论： 脾氨肽口服溶液早期干预治疗可能改善患者季节性过敏性鼻炎的鼻部症状和眼部症状，减少发作期用药，改善患者的生活质量，其可能通过降低患者血清中IL-17A的表达水平从而发挥免疫调节作用。.

BACKGROUND: Allergic rhinitis (AR) or seasonal allergy characterized by sneezing, nasal congestion, nasal itching, and nasal discharge, triggered by immune reactions to environmental allergens. Present day customers also monitor the personal improvements in the area of Evidence-Based natural medicines/supplements.
METHODS: A randomized, double-blind, placebo-controlled study was conducted on 65 participants aged 18 to 60 years having 2 or more allergic symptoms like sneezing, rhinorrhoea, nasal obstruction, and nasal itching for a cumulative period greater than 1 hour per day. The study participants received a capsule of NSO (250 mg) with 2.5 mg piperine (BioPerine) as a bioavailability enhancer or a placebo, twice a day, after food for 15 days. The primary objectives were evaluated by mean change in Total Nasal Symptom Score and the duration of AR symptoms per day from baseline to Day 15. Secondary endpoints were changes in Total Ocular Symptoms Score, AR symptom frequency and severity, serum Immunoglobulin E levels, and Patient Global Impression of Change scale. Adverse events were monitored throughout the study.
RESULTS: Sixty-five patients were enrolled and all of them completed the study, N = 33 in NSO and N = 32 in placebo. A significant reduction in Total Nasal Symptom Score and Total Ocular Symptoms Score was observed in the NSO group compared to the placebo, highlighting the potential of NSO in alleviating AR symptoms. The episodes of AR symptoms per day and the frequency of symptoms in 24 hours reduced significantly in 15 days in both groups, but the extent of improvement was significantly higher in NSO compared to placebo. Improvement in Patient Global Impression of Change was also significantly better in NSO compared to the placebo. Serum Immunoglobulin E levels decreased in NSO but were not significantly different from placebo. No clinically significant changes were observed in vital signs, liver and renal function, lipid profile, hematology, fasting blood sugar, or urine analysis at the end of the study.
CONCLUSIONS: The result of the study demonstrates that NSO 250 mg with 2.5 mg piperine is an effective and well-tolerated supplement for the management of AR symptoms.

UNASSIGNED: Atopic diseases have been steadily increasing over the past decades and effective disease-modifying treatment options are urgently needed. These studies introduce a novel synthetic Toll-like receptor 4 (TLR4) agonist, INI-2004, with remarkable efficacy as a therapeutic intranasal treatment for seasonal allergic rhinitis.
UNASSIGNED: Using a murine airway allergic sensitization model, the impact of INI-2004 on allergic responses was assessed.
UNASSIGNED: One or two intranasal doses of INI-2004 significantly reduced airway resistance, eosinophil influx, and Th2 cytokine production - providing strong evidence of allergic desensitization. Further investigations revealed that a liposomal formulation of INI-2004 exhibited better safety and efficacy profiles compared to aqueous formulations. Importantly, the liposomal formulation demonstrated a 1000-fold increase in the maximum tolerated intravenous dose in pigs. Pre-clinical GLP toxicology studies in rats and pigs confirmed the safety of liposomal INI-2004, supporting its selection for human clinical trials.
UNASSIGNED: These findings lay the groundwork for the ongoing clinical evaluation of INI-2004 in allergic rhinitis as a stand-alone therapy for individuals poly-sensitized to multiple seasonal allergens. The study underscores the significance of innovative immunotherapy approaches in reshaping the landscape of allergic rhinitis management.

变应性鼻炎是严重影响人民群众健康和生活质量的多发病。花粉是引发季节性变应性鼻炎的重要过敏原，严重影响患者个体日常生活、工作和学习质量，带来沉重的医疗和社会负担。建立高效、快速的大气花粉监测系统和可靠的评估过敏风险指标对于变应性疾病的防控尤为重要。本文概述了国际大气花粉监测的方法，以及我国大气花粉监测的发展和现状。.

BACKGROUND: Exposure to air pollution can affect the health of individuals with respiratory disease, but may also impede the health and performance of athletes. This is potentially relevant for people travelling to and competing in the Olympic and Paralympic Games (OPG) in Paris. We describe anticipated air quality in Paris based on historical monitoring data and describe the impact of the process on the development of monitoring strategies for future international sporting events.
METHODS: Air pollutant data for July to September 2020-2023 and pollen data for 2015-2022 were provided by Airparif (particulate matter (PM2.5), nitrogen dioxide (NO2) and ozone (O3)) and RNSA stations in the Paris region. Airparif\'s street-level numerical modelling provided spatial data for the OPG venues.
RESULTS: The maximum daily mean PM2.5 was 11±6 µg/m3 at traffic stations, below the WHO recommended daily air quality threshold (AQT). Daily NO2 concentrations ranged from 5±3 µg/m3 in rural areas to 17±14 µgm3 in urban areas. Near traffic stations, this rose to 40±24 µg/m3 exceeding the WHO AQT. Both peaked around 06:00 and 20:00 UTC (coordinated universal time). The ambient O3 level exceeded the AQT on 20 days per month and peaked at 14:00 UTC. The main allergenic taxa from June to September was Poaceae (ie, grass pollen variety).
CONCLUSIONS: Air pollutant levels are expected to be within accepted air quality thresholds at the Paris OPG. However, O3 concentrations may be significantly raised in very hot and clear conditions and grass pollen levels will be high, prompting a need to consider and manage this risk in susceptible individuals.

UNASSIGNED: Seasonal allergies have a negative impact on patients\' quality of life. Nurses must be aware of the different treatment options and lifestyle modifications to help patients manage their symptoms. This article discusses the benefits and risks of over-the-counter medications for seasonal allergies and other implications for nurses.

UNASSIGNED: Polymerized allergoids conjugated with mannan represent a novel approach of allergen immunotherapy targeting dendritic cells. In this study, we aimed to determine the optimal dose of mannan-allergoid conjugates derived from grass pollen (Phleum pratense and Dactylis glomerata) administered via either the subcutaneous or sublingual route.
UNASSIGNED: A randomized, double-blind, placebo-controlled trial with a double-dummy design was conducted, involving 162 participants across 12 centers in Spain. Subjects were randomly allocated to one of nine different treatment groups, each receiving either placebo or active treatment at doses of 500, 1,000, 3,000, or 5,000 mTU/mL over four months. Each participant received five subcutaneous (SC) doses of 0.5 mL each, every 30 days, and a daily sublingual (SL) dose of 0.2 mL. Participants who received active treatment through SC, received placebo through SL. Participants who received active treatment through SL, received placebo SC. One Group, as control, received bot SC and SL placebo. The primary efficacy outcome was the improvement in titrated nasal provocation tests (NPT) at the end of the study compared to baseline. Secondary outcomes included specific antibody (IgG4, IgE) and cellular (IL-10 producing and regulatory T cell) responses. All adverse events and side reactions were recorded and assessed.
UNASSIGNED: Post-treatment, the active groups showed improvements in NPT ranging from 33% to 53%, with the highest doses showing the greatest improvements regardless of the administration route. In comparison, the placebo group showed a 12% improvement. Significant differences over placebo were observed at doses of 3,000 mTU/mL (p=0.049 for SL, p=0.015 for SC) and 5,000 mTU/mL (p=0.011 for SL, p=0.015 for SC). A dose-dependent increase in IgG4 was observed following SC administration, and an increase in IL-10 producing cells for both routes of administration. No serious systemic or local adverse reactions were recorded, and no adrenaline was required.
UNASSIGNED: Grass pollen immunotherapy with mannan-allergoid conjugates was found to be safe and efficacious in achieving the primary outcome, whether administered via the subcutaneous or sublingual routes, at doses of 3,000 and 5,000 mTU/mL.
UNASSIGNED: https://www.clinicaltrialsregister.eu/ctr-search (EudraCT), identifier 2014-005471-88; https://www.clinicaltrials.gov, identifier NCT02654223.

暂无摘要。

BACKGROUND: Molecular diagnosis in allergology helps to identify multiple allergenic molecules simultaneously. The use of purified and/or recombinant allergens increases the accuracy of individual sensitization profiles in allergic patients.
OBJECTIVE: To assess the impact of molecular diagnosis through the ImmunoCAPTM ISAC 112 microarray on etiological diagnosis and specific immunotherapy (SIT) prescription. This was compared to the use of conventional diagnoses in pediatric, adolescent, and young adult patients with rhinitis or rhinoconjunctivitis and/or allergic asthma, sensitized to three or more pollen allergens of different botanical species.
METHODS: A multicenter, prospective, observational study was conducted in patients aged 3-25 years who received care at the Allergology service of 14 hospitals in Catalonia from 2017 to 2020. Allergology diagnosis was established based on the patient\'s clinical assessment and the results of the skin prick test and specific immunoglobulin E assays. Subsequently, molecular diagnosis was conducted using ImmunoCAPTM ISAC® 112 to recombinant and/or purified allergen components.
RESULTS: A total of 109 patients were included; 35 (32.1%) were pediatric patients and 74 (67.9%) were adolescents or young adults (mean age: 18 years), with 58.0% being females. A change of 51.0% was observed in SIT prescription following molecular etiological diagnosis by means of a multi-parameter microarray.
CONCLUSIONS: Molecular diagnosis by means of multi-parameter tests increases the accuracy of etiological diagnosis and helps to define an accurate composition of SIT.

This study was to investigate the relationship between spring pollen distribution concentration, species and the detection results of air-borne pollen allergens in Taiyuan City, Shanxi Province during March to May 2022 and March to May 2023.A retrospective study was conducted in the Otorhinolaryngology Head and Neck Surgery Clinic of the First Hospital of Shanxi Medical University.Pollen particles will be monitored by gravity sedimentation method on the roof of the outpatient department of the First Hospital of Shanxi Medical University in downtown Taiyuan from March to May 2022-2023, and pollen species and quantity will be observed and recorded under an optical microscope.The air-borne pollen allergen detection results of all allergic rhinitis patients in the otolaryngology Head and Neck surgery Department of the First Hospital of Shanxi Medical University were extracted from the relevant outpatient system. SPSS software and Pearson correlation analysis were used to compare the correlation between the allergens and the dominant air-borne pollen monitoring results. Results are as follows: (1)A total of 18 species of spring pollen in Taiyuan City were monitored in 2022-2023, with 101 177.5 grains, and the dominant airborne pollen was poplar (16.69%) and pine (29.06%) pollen. The pollen of poplar (11.96%), elm (7.89%) and cypress (8.68%) were dominant in early spring; Pine (25.16%) pollen predominated in late spring. The two peaks of pollen dispersal in Taiyuan were in late March (15 479 grains) and early and mid May (15 094/15 343 grains).(2) The positive rates of allergens in serum specific IgE detection were: wormwood (46%, 248/541 cases), tree combination (26%, 143/541 cases), ragweed (19%, 101/541 cases), humulus scandens (9%, 49/541 cases).(3)There was a linear positive correlation between the positive rate of air-borne pollen allergens in allergic rhinitis patients in the Department of Otolaryngology Head and Neck Surgery in the First Hospital of Shanxi Medical University and the dominant air-borne pollen concentration in the same period (P<0.05, r=0.999). In conclusion, two spring pollen dispersal peaks were formed in late March and early to mid May in Taiyuan City, and the dominant air-borne pollens were poplar and pine pollens. The positive rate of air borne pollen allergen sIgE showed that wormwood allergy was the highest.There was a positive correlation between the concentration of air-borne pollen and the positive rate of air-borne pollen allergens in patients with allergic rhinitis in the Department of otorhinolaryngology and head and neck surgery in Taiyuan in 2022 and 2023.The monitoring of pollen distribution in spring can provide an important scientific basis for clinical workers to formulate prevention and treatment plans for patients with allergic rhinitis in the season, and provide data reference for the epidemiological investigation of allergic diseases in Taiyuan in the future.
本研究探讨山西省太原市2022年3—5月与2023年3—5月两年间春季花粉播散浓度、种类与患者气传花粉变应原检测结果的关系。采用回顾性研究方法，本研究于山西医科大学第一医院耳鼻咽喉头颈外科门诊展开。2022—2023年两年的3—5月在位于太原市中心地区的山西医科大学第一医院门诊部楼顶，利用重力沉降法监测花粉颗粒，并在光学显微镜下观察记录花粉种类和数量。从门诊相关系统中提取所有同期山西医科大学第一医院耳鼻咽喉头颈外科门诊过敏性鼻炎患者气传花粉变应原检测结果，利用SPSS软件并采用Pearson 相关性分析法比较其与优势气传花粉监测结果之间的相关性。结果显示，（1）共监测到2022—2023两年太原市春季花粉18种，101 177.5粒，优势气传花粉为杨树（16.69%）和松树（29.06%）花粉。早春以杨树（11.96%）、榆树（7.89%）、柏树（8.68%）花粉播散为主；晚春以松树（25.16%）花粉为主。太原市花粉播散两个高峰期为3月下旬（15 479粒）与5月上中旬（15 094/15 343粒）。（2）变应原血清特异性IgE检测中，变应原的检出阳性率依次是：蒿草（46%，248/541例）、树木组合（26%，143/541例）、豚草（19%，101/541例）、葎草（9%，49/541例）。（3）山西医科大学第一医院耳鼻咽喉头颈外科门诊过敏性鼻炎患者气传花粉变应原检测结果阳性率与同期优势气传花粉浓度之间存在线性正相关（P<0.05，r=0.999）。综上，太原市3月下旬与5月上中旬形成两个春季花粉播散高峰期，优势气传花粉为杨树和松树花粉；气传花粉变应原sIgE结果阳性率显示蒿草过敏阳性率最高；2022—2023年两年间太原春季优势气传花粉浓度同耳鼻咽喉头颈外科门诊过敏性鼻炎患者的气传花粉变应原检测结果阳性率呈正相关。春季花粉播散规律的监测，能为制定当季过敏性鼻炎患者预防与治疗方案提供重要依据，并为今后太原市过敏性疾病的流行病学调查提供数据参考。.